Please note that log in for BLAW products will be unavailable for scheduled maintenance on Sunday, February 5th from approximately 4 AM to 5 AM EST.
Bloomberg Law
Free Newsletter Sign Up
Login
BROWSE
Bloomberg Law
Welcome
Login
Advanced Search Go
Free Newsletter Sign Up

Otsuka, Lundbeck Sue Viatris Again on Abilify Maintena Copy (1)

Aug. 29, 2022, 6:38 PMUpdated: Aug. 29, 2022, 8:47 PM

Otsuka Holdings Co. and H. Lundbeck AS expanded their legal fight over Viatris Inc.’s proposed generic version of Abilify Maintena, alleging in Delaware federal court that it infringes a patent issued May 31 for the monthly injectable treatment for schizophrenia that Lundbeck exclusively licenses from Otsuka.

Otsuka and Lundbeck filed the complaint against Viatris, formerly known as Mylan, Aug. 26 in the US District Court for the District of Delaware. It follows two April lawsuits involving the same parties that were filed in Delaware and the Northern District of West Virginia over eight other patents for the drug. The ...